Clinical Trial Update: AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of sotorasib (AMG510) and lenvatinib in KRAS G12C-mutant metastatic non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AMG510 (sotorasib) (sotorasib)
• LENVIMA (lenvatinib)

Snippet

Sponsor: ETOP IBCSG Partners Foundation | Conditions: Metastatic Non Small Cell Lung Cancer, KRAS G12C | Phase 2 | Status: WITHDRAWN